Skip to main content

Table 1 Clinical, laboratory and radiographic characteristics

From: Comparative study of the synovial levels of RANKL and OPG in rheumatoid arthritis, spondyloarthritis and osteoarthritis

 

Rheumatoid arthritis (n = 33)

Spondyloarthritis (n = 32)

Osteoarthritis (n = 18)

p-value

Demographics

Female [n (%)]

28 (85)

8 (25)

18 (100)

N/A

Age [years; median (IQR)]

57.0 (20–82)

46.5 (18–74)

68.0 (49–82)

N/A

Time of disease < 2 years [n (%)]

8 (24)

12 (37)

4 (22)

N/A

Comorbidities

Smoking [n (%)]

13 (40)

5 (15)

5 (28)

N/A

Cardiovascular diseases [n (%)]

21 (64)

13 (40)

12 (66)

N/A

Diabetes mellitus [n (%)]

2 (6)

3 (9)

3 (16)

N/A

Dyslipidemia [n (%)]

4 (12)

3 (9)

2 (11)

N/A

Obesity [n (%)]

4 (12)

2 (6)

5 (27)

N/A

Fibromyalgia [n (%)]

5 (15)

1 (3)

2 (11)

N/A

Laboratory findings

CRP [mg/dL; median (IQR)]

0.95 (0.4–3.1)

1.2 (0.6–6.3)

1.9 (0.5–3.4)

ns

CRP > 1.0 [mg/dL; n (%)]

16 (48)

17 (53)

10 (55)

ns

ESR [mm/h; median (IQR)]

23 (7–37)

19 (8–40.7)

20 (6–26)

ns

ESR > 20 [mm/h; n (%)]

18 (54.5)

15 (46.8)

7 (38.8)

ns

Cell count [/mm3; median (IQR)]

7675 (862–16950)

8400 (2475–16,825)

800 (250–1225)

< 0.01

Neutrophils [/mm3; median (IQR)]

77 (62–85)

72 (52–88)

70 (43–76)

ns

Medications

Methotrexate [n (%)]

8 (25)

2 (6)

ns

Leflunomide [n (%)]

8 (25)

1 (3)

ns

Sulfasalazine [n (%)]

1 (3)

5 (28)

ns

TNF-blocker [n (%)]

10 (30)

16 (50)

ns

Non TNF-blocker [n (%)]

6 (18)

1 (3)

ns

  1. IQR interquartile range, CRP C-reactive protein, ESR Erythrocyte sedimentation rate